LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Syndax Pharmaceuticals Inc

Closed

SectorHealthcare

11.47 3.33

Overview

Share price change

24h

Current

Min

11.42

Max

11.56

Key metrics

By Trading Economics

Income

9.3M

-85M

Sales

12M

20M

EPS

-0.985

Profit margin

-423.341

Employees

270

EBITDA

5.6M

-84M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+175.11% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-237M

945M

Previous open

8.14

Previous close

11.47

News Sentiment

By Acuity

67%

33%

342 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Syndax Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 lip 2024, 12:35 UTC

Major Market Movers

Syndax Pharma Shares Fall Premarket After FDA Extends Revumenib Review

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

175.11% upside

12 Months Forecast

Average 31.5 USD  175.11%

High 45 USD

Low 17 USD

Based on 7 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

9.91 / 14.15Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

342 / 380 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.